Palisade Bio PALI
NASDAQ PALI
$1.17 +0.04 (+3.54%)
At close: Nov 11, 2026 · 4:00 PM EST

Palisade Bio (PALI) Gains from Sales and Divestitures (2024)

Updated

Palisade Bio (PALI) posted Gains from Sales and Divestitures of -$4,000 for FY2024.

Analysis

Palisade Bio (PALI) Gains from Sales and Divestitures (2024) Analysis & Trends

Since FY2016, Palisade Bio has reported Gains from Sales and Divestitures for 4 years.

  • The FY2024 figure stands as the lowest annual Gains from Sales and Divestitures since FY2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Palisade Bio 239.59 Mn -265.23 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 -4,000.00
API Access

Palisade Bio Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=PALI&period=max&api_key=YOUR_API_KEY